Should low-dose combination therapy be a preferred first-line treatment for hypertension: predicting JNC VIICombination therapyIn JNC-6, low-dose combination therapy is said to be "appropriate" for initial treatment of hypertension, stating that "combinations of low doses of two agents from ...
First-line medicines in the treatment of hypertensionNPS MedicineWise
line treatment for hypertension: Meta- analysis and economic evaluation (Tran et al. [16]) Thiazides, CCB, BB, ACEI or ARB and no therapy For the base case analysis, the cohorts included men and women, 55–65 years old, with baseline SBP of 150 mmHg or 180 mmHg, all were non ...
Hypertension: are the beta-blockers and diuretics appropriate first line treatment? Ann Pharmacother. 1994;28:617-625.Wilson MD. Weart CW. Hypertension: Are beta-blockers and diuret- ics appropriate first-line therapies? Ann Phannaco!hrr. 1994;28:617-6 25....
Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study. Lancet Oncol 2015;16:1547-55.Jabbour E, Kantarjian H, Ravandi F, et al. Combination of hyper- CVAD with ponatinib as...
Lowering of the blood pressure limit that represents adequate control of hypertension from 140/90mmHg to 130/85mmHg has inevitably worsened the recorded rates of control among hypertensive patients: patients who were considered controlled at 140/90mmHg are no longer considered controlled, so the ...
“KEYTRUDA plus LENVIMA continues to demonstrate durable clinical benefit as a first-line treatment for patients with advanced renal cell carcinoma, as shown by the clinically meaningful improvement in overall survival ...
Folliculogenesis can be restored by several drugs, and medical treatment will have a "positive" reproductive effect sooner than lifestyle modification. That said, a pregnancy in an uncontrolled metabolic state is at a significantly higher risk.Miscarriagerates are greater, hypertension and diabetes occur...
95 : Treprostinil as first-line treatment in severe pulmonary arterial hypertension: Effects on clinical outcome and survivaldoi:10.1016/j.healun.2005.11.100C.JimenezandP.EscribanoandM.D.MartinandJ.F.SDOSJournal of Heart & Lung Transplantation...
Less hypertension has been reported with nintedanib but nausea, diarrhoea and abnormal liver function were the most frequently described side-effects using 250 mg bd [55]. The dose in the first-line study is 200 mg. Targeting the angiopoietin axis is another strategy to develop anti-angiogenic ...